Search

Your search keyword '"Mesencephalon drug effects"' showing total 2,248 results

Search Constraints

Start Over You searched for: Descriptor "Mesencephalon drug effects" Remove constraint Descriptor: "Mesencephalon drug effects"
2,248 results on '"Mesencephalon drug effects"'

Search Results

1. Functional Adaptation in the Brain Habenulo-Mesencephalic Pathway During Cannabinoid Withdrawal.

2. Conditional deletion of the AMPA-GluA1 and NMDA-GluN1 receptor subunit genes in midbrain D1 neurons does not alter cocaine reward in mice.

3. Presynaptic and Postsynaptic Mesolimbic Dopamine D 3 Receptors Play Distinct Roles in Cocaine Versus Opioid Reward in Mice.

4. Engineering human midbrain organoid microphysiological systems to model prenatal PFOS exposure.

5. Developmental origins of Parkinson's disease risk: perinatal exposure to the organochlorine pesticide dieldrin leads to sex-specific DNA modifications in critical neurodevelopmental pathways in the mouse midbrain.

6. Tilorone mitigates the propagation of α-synucleinopathy in a midbrain-like organoid model.

7. Acute Ongoing Nociception Delays Recovery of Consciousness from Sevoflurane Anesthesia via a Midbrain Circuit.

8. Mitochondrial transfer of α-synuclein mediates carbon disulfide-induced mitochondrial dysfunction and neurotoxicity.

9. Paraquat disrupts KIF5A-mediated axonal mitochondrial transport in midbrain neurons and its antagonism by melatonin.

10. Chronic Opioid Treatment Arrests Neurodevelopment and Alters Synaptic Activity in Human Midbrain Organoids.

11. Sex differences in neuronal activation in the cortex and midbrain during quinine-adulterated alcohol intake.

12. The Angiotensin Antagonist Losartan Modulates Social Reward Motivation and Punishment Sensitivity via Modulating Midbrain-Striato-Frontal Circuits.

13. The dopamine receptor agonist apomorphine stabilizes neurotoxic α-synuclein oligomers.

14. Targeted activation of midbrain neurons restores locomotor function in mouse models of parkinsonism.

15. Multi-omic landscaping of human midbrains identifies disease-relevant molecular targets and pathways in advanced-stage Parkinson's disease.

16. Chronic nicotine increases midbrain dopamine neuron activity and biases individual strategies towards reduced exploration in mice.

17. Rapid immunohistological measurement of tyrosine hydroxylase in rat midbrain by near-infrared instrument-based detection.

18. The gating pore blocker 1-(2,4-xylyl)guanidinium selectively inhibits pacemaking of midbrain dopaminergic neurons.

19. Noradrenergic alpha-2A receptor activation suppresses courtship vocalization in male Japanese quail.

20. IGF-1 receptor is involved in the regulatory effects of icariin and icaritin in astrocytes under basal conditions and after an inflammatory challenge.

21. Protective effect of plastrum testudinis extract on dopaminergic neurons in a Parkinson's disease model through DNMT1 nuclear translocation and SNCA's methylation.

22. Thyroid hormone deficiency during zebrafish development impairs central nervous system myelination.

23. Pharmacological evaluation of vanillic acid in rotenone-induced Parkinson's disease rat model.

24. Folic acid supplementation rescues valproic acid-induced developmental neurotoxicity and behavioral alterations in zebrafish embryos.

25. Quinacrine and Niclosamide Promote Neurite Growth in Midbrain Dopaminergic Neurons Through the Canonical BMP-Smad Pathway and Protect Against Neurotoxin and α-Synuclein-Induced Neurodegeneration.

26. Altered heparan sulfate metabolism during development triggers dopamine-dependent autistic-behaviours in models of lysosomal storage disorders.

27. Oral subchronic exposure to the mycotoxin ochratoxin A induces key pathological features of Parkinson's disease in mice six months after the end of the treatment.

28. Aromatic-Turmerone Analogs Protect Dopaminergic Neurons in Midbrain Slice Cultures through Their Neuroprotective Activities.

29. Evaluation of efficiency omega 3 fatty acid improves the behavioural phenotype and protects against oxidative stress against MPP+ induces Parkinson's disease in mice.

30. Bidirectional sex-dependent regulation of α6 and β3 nicotinic acetylcholine receptors by protein kinase Cε.

31. Mechanistic insights into the protective effect of paracetamol against rotenone-induced Parkinson's disease in rats: Possible role of endocannabinoid system modulation.

32. A- and D-type potassium currents regulate axonal action potential repolarization in midbrain dopamine neurons.

33. Promotive effects of tetrahydroxystilbene glucoside on the differentiation of neural stem cells from the mesencephalon into dopaminergic neurons.

34. Psilocybin exerts distinct effects on resting state networks associated with serotonin and dopamine in mice.

35. Computational and theoretical insights into the homeostatic response to the decreased cell size of midbrain dopamine neurons.

36. Characterization of the antiapoptotic effect of copper sulfate on striatal and midbrain damage induced by MPP + in rats.

37. Progress in opioid reward research: From a canonical two-neuron hypothesis to two neural circuits.

38. TRIM3 attenuates apoptosis in Parkinson's disease via activating PI3K/AKT signal pathway.

39. Evaluation of the Cytotoxicity of Ayahuasca Beverages.

40. Interplay of Prenatal and Postnatal Risk Factors in the Behavioral and Histological Features of a "Two-Hit" Non-Genetic Mouse Model of Schizophrenia.

41. Serotonergic treatment normalizes midbrain dopaminergic neuron increase after periaqueductal gray stimulation.

42. Effects of Combined Bushen Zhichan Recipe and Levodopa in a Rodent Model of Parkinson Disease: Potential Mechanisms.

43. Machine learning-assisted neurotoxicity prediction in human midbrain organoids.

44. Region-specific effects of acute haloperidol in the human midbrain, striatum and cortex.

45. TGF-β Signaling Regulates SLC8A3 Expression and Prevents Oxidative Stress in Developing Midbrain Dopaminergic and Dorsal Raphe Serotonergic Neurons.

46. The onjisaponin B metabolite tenuifolin ameliorates dopaminergic neurodegeneration in a mouse model of Parkinson's disease.

47. Endocannabinoids mediate long-lasting behavioural and physiological changes in male rats induced by the repeated activation of the mesolimbic system by copulation to satiety.

48. Characterization of AN317, a novel selective agonist of α6β2-containing nicotinic acetylcholine receptors.

49. Cocaine abuse and midbrain circuits: Functional anatomy of hypocretin/orexin transmission and therapeutic prospect.

50. JWH133 inhibits MPP + -induced inflammatory response and iron influx in astrocytes.

Catalog

Books, media, physical & digital resources